摘要
目的比较海藻酸钾散剂与寿比山治疗原发性高血压的疗效及安全性。方法采用随机、双盲、配对、组间平行对照的方法,海藻酸钾散剂组和寿比山组各76例。海藻酸钾散剂组给药3g,每日2次,逐渐增量,最大剂量为每日8g。寿比山组给予寿比山每次2.5mg,每日1次,两组疗程均为8周。结果两组治疗后第1周、第4周、第8周收缩压及舒张压均较用药前显著降低(P<0.01)。海藻酸钾组降压幅度收缩压为21.59mmHg,舒张压为10.15mmHg;寿比山组降压幅度收缩压为25.27mmHg,舒张压为11.15mmHg,两组收缩压及舒张压下降幅度比较均无统计学意义。海藻酸钾散剂降压的总有效率为75.0%,寿比山组为67.1%(P>0.05)。海藻酸钾散剂组无明显不良反应,且对各生化指标、心率及心电图均无影响。结论海藻酸钾散剂与寿比山具有相似的降压疗效,是一种安全、有效的降压药。
Objective To compare the efficacy and safety of potassium alginate and indapamid for hypertension, Methods One hundred and fifty two patients （pts） were randomized to receive either potassium alginate（ n = 76,3 g-8 g, Bid） or indapamide （2.5 mg once daily） for 8 weeks. Blood pressure （BP） and side effects were analyzed. Results In the potassium alginate and indapamide group, systolic and diastolic blood pressure in first and eighth weeks after treatment were lower significantly than that before treatment（ P〈0.01 ）. Decrease of systolic and diastolic blood pressure was 21.59 mmHg and 10, 15 rnmHg respectively in the potassium alginate group. And that were 25.27 mmHg and 11, 15 mmHg respectively in indapamide groups, There was no significant difference. In the eighth week, normotension was achieved in 75.0% of pts in potassium alginate, and 67.1% of pts in indaparnide. There was no significant difference between two groups, Obvious side effects were not observed in the potassium alginate group. Conclusion The efficacy and safety of potassium alginate for hypertension was similar to indapamide.
出处
《中西医结合心脑血管病杂志》
2006年第7期565-566,共2页
Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
